Diverging Views Emerge on Abbott Laboratories' Stock Outlook

Major funds increase Abbott holdings despite a lowered price target. Q4 revenue missed estimates, but medical devices grew. The stock is down 10% YTD.

The investment landscape for Abbott Laboratories, the U.S.-based medical technology conglomerate, is presenting a complex picture. A notable divergence has appeared between the actions of major institutional shareholders and the near-term adjustments from Wall Street analysts, creating mixed signals for the long-standing dividend-paying stock.

Institutional Accumulation Amid Analyst Caution

Recent regulatory filings reveal a clear trend of institutional buying. Several major investment firms have significantly increased their holdings in Abbott Laboratories:

• Franklin Resources boosted its position by 8.8%, bringing its total to approximately 10.3 million shares.
• Mackenzie Financial grew its stake by 2.0%, now holding 1.5 million shares.
• Capital World Investors added a further 0.5%, accumulating 8.9 million shares.

This activity has contributed to institutional investors now controlling over 75% of the company's outstanding shares. Their buying contrasts with a recent, more cautious analytical review. Citigroup analyst Joanne Wuensch recalibrated her price target, lowering it from $140 to $136, though she maintained a "Buy" rating. Wuensch cited a broader sector re-evaluation as the reason, while affirming that the fundamental outlook for the medtech industry remains solid.

Quarterly Performance Shows Strengths and Challenges

The slightly tempered analyst sentiment follows Abbott's latest financial results. For the final quarter of 2025, the company posted revenue of $11.46 billion, a 4.4% year-over-year increase. This figure, however, fell short of market consensus estimates of $11.80 billion. A primary growth engine was the medical devices division, where continuous glucose monitoring (CGM) products delivered a substantial $2.0 billion in quarterly sales.

Concurrently, the company navigated operational challenges within its diabetes care unit. A recall affecting about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors drew attention due to a manufacturing issue that could cause falsely low glucose readings. Abbott has since resolved the production flaw. This blend of robust segment performance and specific product setbacks is mirrored in the stock's price action; shares have declined roughly 10% since the start of the year, closing yesterday at just over €95.

Strategic Moves and Shareholder Returns on the Horizon

Looking ahead, Abbott's management has provided 2026 earnings per share guidance in the range of $5.55 to $5.80. Strategic focus is sharpening on the second quarter, when the company expects to finalize its $21 billion acquisition of Exact Sciences. This deal is poised to significantly expand Abbott's footprint in the diagnostics market.

In the interim, the company continues to return capital to shareholders through its established program. The next quarterly dividend payment of $0.63 per share is scheduled for April 15, 2026.